JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

MannKind Corp

Closed

SectorHealthcare

3.99 0.76

Overview

Share price change

24h

Current

Min

3.87

Max

4.04

Key metrics

By Trading Economics

Income

5.7M

13M

Sales

1.6M

78M

P/E

Sector Avg

39.2

34.393

Profit margin

16.793

Employees

403

EBITDA

8.3M

27M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+124.49% upside

Dividends

By Dow Jones

Next Earnings

6 sie 2025

Market Stats

By TradingEconomics

Market Cap

-316M

1.2B

Previous open

3.23

Previous close

3.99

News Sentiment

By Acuity

50%

50%

176 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

MannKind Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 sie 2025, 23:11 UTC

Earnings

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 sie 2025, 22:45 UTC

Earnings

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 sie 2025, 22:39 UTC

Earnings

Great-West Lifeco Logs Lower 2Q Profit

5 sie 2025, 21:32 UTC

Earnings

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 sie 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 sie 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 sie 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 sie 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 sie 2025, 23:48 UTC

Market Talk

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 sie 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 sie 2025, 23:19 UTC

Market Talk

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 sie 2025, 23:03 UTC

Market Talk
Earnings

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 sie 2025, 22:22 UTC

Earnings

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 sie 2025, 22:21 UTC

Earnings

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 sie 2025, 22:20 UTC

Earnings

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 sie 2025, 22:18 UTC

Earnings

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 sie 2025, 22:17 UTC

Earnings

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 sie 2025, 22:17 UTC

Earnings

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 sie 2025, 22:16 UTC

Earnings

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 sie 2025, 22:16 UTC

Earnings

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 sie 2025, 22:15 UTC

Earnings

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 sie 2025, 22:13 UTC

Earnings

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 sie 2025, 22:13 UTC

Earnings

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 sie 2025, 22:12 UTC

Earnings

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 sie 2025, 22:12 UTC

Earnings

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 sie 2025, 21:58 UTC

Earnings

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 sie 2025, 21:30 UTC

Earnings

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 sie 2025, 21:26 UTC

Earnings

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 sie 2025, 21:23 UTC

Earnings

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 sie 2025, 21:17 UTC

Earnings

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

124.49% upside

12 Months Forecast

Average 8.8 USD  124.49%

High 11 USD

Low 7 USD

Based on 5 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

4.079 / 4.323Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

176 / 374 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.